Advanced Prostate Cancer

A Surprise About Minority and Majority Attitudes Regarding Clinical Trials and Its Relationship to Prostate Cancer Survivors Willingness to Participate in Clinical Trials

It is commonly known that our current clinical trials struggle to enroll adequate numbers of minority men. Our inability to enroll a cross section of men that truly reflects the general population in prostate cancer clinical trials means that our results might not accurately reflect the best information for a minority man. The lack of [...]

By |2020-02-04T11:38:40-05:00October 9th, 2015|Advanced Prostate Cancer, Clinical Trials, Clinical Trials & Research, General Information, Uncategorized|0 Comments
Read More

Malecare and the New York State Prostate Cancer Coalition Are Victorious and Force the Hand of New York State Governor Andrew Cuomo to Fund $3,000,000 Towards Prostate Cancer Research

Approximately 2 years ago Malecare and the New York State Prostate Coalition began asking questions about where the State of New York was hiding approximately $3,000,000 in funding for prostate cancer research. Each year New York State residents are asked to check off a little box on their state tax return donating an additional dollar [...]

By |2017-10-19T10:46:55-04:00October 8th, 2015|Advanced Prostate Cancer, Advocacy, Clinical Trials & Research, Financial, Politics of Cancer, Research, Uncategorized|0 Comments
Read More

Chemotherapy After Radium-223 Appears to be Safe in Men with Metastatic Castration-Resistant Prostate Cancer

  Understanding how to best sequence and combine our new drugs to treat advanced prostate cancer includes the most discussed issue, efficacy. We want to know if a special order or a special combination of the approved drugs will nake a difference in both our quality of life (QoL) as well as how survival. Often [...]

By |2015-09-30T10:21:06-04:00September 30th, 2015|Advanced Prostate Cancer, Chemotherapy, Combination Therapy, Drugs & Treatments, radiopharmaceuticals, Research, Survival, Uncategorized, Understanding Advanced Prostate Cancer, Xofigo|0 Comments
Read More

Abiraterone Is Effective In Men Over 75 Years Who Are Chemotherapy-Naive And Have mCRPC

We know that Abiraterone (Zytiga) extends life, but we also know that its side effects can be harsh, especially in elderly men (men over 75 years). We also know that men with metastatic, castrate resistant prostate cancer (mCRPC) have a limited potential life expectancy. Given these facts, it is important to know if, despite being [...]

By |2017-10-19T10:46:55-04:00September 29th, 2015|abiraterone acetate, Advanced Prostate Cancer, Drugs & Treatments, Research, Uncategorized, Understanding Advanced Prostate Cancer, Zytiga|0 Comments
Read More

Understanding and Trying to Rectify the Abusive Costs of Our Drugs

I have been relatively quiet about the skyrocketing cost of drugs, but it has now become impossible to remain out of the fray. A Pharmaceutical company recently acquired a drug called Daraprim, the drug treats potentially fatal parasitic infections.   After its acquisition the company raised the price of Daraprim by almost 5,0000%. When confronted with [...]

By |2017-10-19T10:46:55-04:00September 28th, 2015|Advanced Prostate Cancer, Advocacy, Drugs & Treatments, Financial, Insurance, Medical Insurance, Medicare/Medicaid, Politics of Cancer, Survival, Uncategorized|0 Comments
Read More

Radium-223 When Given In Combinations May Improve Survival in mCRPC

As I have said before, the next big step in the clinical care of men with prostate cancer will be in not in the development of a new drug, but in our growing knowledge of how to sequence and combine our new drugs. Today’s post provides just one example of this new type of breakthrough [...]

By |2020-02-04T11:45:46-05:00September 26th, 2015|Advanced Prostate Cancer, bisphosphonates, Bone Metastases, Bones and Prostate Cancer, Chemotherapy, Clinical Trials & Research, Combination Therapy, Drugs & Treatments, radiopharmaceuticals, Survival, Uncategorized, Understanding Advanced Prostate Cancer, Xofigo, Xtandi, Zytiga|0 Comments
Read More

The Really Big Question We all Ask, Will I Die from Prostate Cancer?

Because of the large amount of prostate cancer screening there has been a major shift in initial staging in prostate cancer  in western countries, with the incidence of metastases at diagnosis decreasing from over 50% in the 1970s to currently less than 10%.  Despite this very significant drop in late stage diagnoses prostate cancer is [...]

By |2017-10-19T10:46:55-04:00September 25th, 2015|Advanced Prostate Cancer, biomarkers, Bone Metastases, General Information, Research, Uncategorized, Understanding APC|0 Comments
Read More

Is There A Clinical Benefit Derived From Using Low Dose Prednisone With First Line Docetaxel Treatment In Men With Castrate Resistant Prostate Cancer?

There have been some randomized studies that have shown that when prednisone is used in combination with docetaxel (chemotherapy) there is an improved survival in men who have metastatic castration-resistant prostate cancer (mCRPC). To add to our understanding of the possible clinical value of this combination of drugs some researchers have retrospectively evaluated whether the [...]

By |2020-02-04T11:38:36-05:00September 24th, 2015|Advanced Prostate Cancer, Chemotherapy, Combination Therapy, docetaxel, edema, neutropenia, Research, Uncategorized|0 Comments
Read More

ADT with Radiation Treatment Might Endanger Your Life!

The standard of care and the facts are simple. Men who have aggressive prostate cancer and elect to have radiation therapy will benefit from six months of concurrent hormone therapy (ADT). However, based on recent findings by D’Amico etal, there seems to be a segment of men who will not benefit, but will have inferior [...]

By |2020-02-04T10:13:01-05:00September 23rd, 2015|Advanced Prostate Cancer, Drugs & Treatments, Radiation, Radiotherapy, Survival, Uncategorized|0 Comments
Read More
Go to Top